CDKN2B expression was significantly reduced in patients with T-ALL (median, 0.221; range, 0.000–4.833) compared with those with normal BM (median, 4.067; range, 2.043–8.721, P < 0.001). Here, CDKN2B is linked to acute lymphoblastic leukemia.